HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.

AbstractBACKGROUND:
Women with node-positive vulvar cancer have a high risk for disease recurrence. Indication criteria for adjuvant radiotherapy are controversial. This study was designed to further understand the role of adjuvant therapy in node-positive disease.
METHODS:
Patients with primary squamous-cell vulvar cancer treated at 29 gynecologic cancer centers in Germany from 1998 through 2008 were included in this retrospective exploratory multicenter cohort study. Of 1618 documented patients, 1249 had surgical groin staging and known lymph node status and were further analyzed. All statistical tests were two-sided.
RESULTS:
Four hundred forty-seven of 1249 patients (35.8%) had lymph node metastases (N+). The majority of N+ patients had one (172 [38.5%]) or two (102 [22.8%]) positive nodes. The three-year progression-free survival (PFS) rate of N+ patients was 35.2%, and the overall survival (OS) rate 56.2% compared with 75.2% and 90.2% in node-negative patients (N-). Two hundred forty-four (54.6%) N+ patients had adjuvant therapy, of which 183 (40.9%) had radiotherapy directed at the groins (+/-other fields). Three-year PFS and OS rates in these patients were better compared with N+ patients without adjuvant treatment (PFS: 39.6% vs 25.9%, hazard ratio [HR] = 0.67, 95% confidence interval [CI[= 0.51 to 0.88, P = .004; OS: 57.7% vs 51.4%, HR = 0.79, 95% CI = 0.56 to 1.11, P = .17). This effect was statistically significant in multivariable analysis adjusted for age, Eastern Cooperative Oncology Group, Union internationale contre le cancer stage, grade, invasion depth, and number of positive nodes (PFS: HR = 0.58, 95% CI = 0.43 to 0.78, P < .001; OS: HR = 0.63, 95% CI = 0.43 to 0.91, P = .01).
CONCLUSION:
This large multicenter study in vulvar cancer observed that adjuvant radiotherapy was associated with improved prognosis in node-positive patients and will hopefully help to overcome concerns regarding adjuvant treatment. However, outcome after adjuvant radiotherapy remains poor compared with node-negative patients. Adjuvant chemoradiation could be a possible strategy to improve therapy because it is superior to radiotherapy alone in other squamous cell carcinomas.
AuthorsSven Mahner, Julia Jueckstock, Felix Hilpert, Petra Neuser, Philipp Harter, Nikolaus de Gregorio, Annette Hasenburg, Jalid Sehouli, Annika Habermann, Peter Hillemanns, Sophie Fuerst, Hans-Georg Strauss, Klaus Baumann, Falk Thiel, Alexander Mustea, Werner Meier, Andreas du Bois, Lis-Femke Griebel, Linn Woelber, AGO-CaRE 1 investigators
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 107 Issue 3 (Mar 2015) ISSN: 1460-2105 [Electronic] United States
PMID25618900 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Copyright© The Author 2014. Published by Oxford University Press.
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy, pathology, radiotherapy)
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Germany
  • Groin
  • Humans
  • Kaplan-Meier Estimate
  • Lymph Nodes (pathology)
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Treatment Outcome
  • Vulvar Neoplasms (drug therapy, pathology, radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: